Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy.

American journal of therapeutics

Volumn 10, Issue 4, 2003, Pages 241-246

  Argenti, Domenick ^a   Hoppensteadt, Debra ^a   Heald, Donald ^a   Jensen, Brad ^a   Fareed, Jaweed ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG INTERACTION; FEMALE; HALF LIFE TIME; HUMAN; MALE; METABOLIC CLEARANCE RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; AREA UNDER CURVE; CORONARY DISEASE; DRUG INTERACTIONS; ENOXAPARIN; FEMALE; HALF-LIFE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; METABOLIC CLEARANCE RATE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0142213601     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200307000-00002     Document Type: Article

References (0)